Results 161 to 170 of about 436,310 (315)

Disseminated varicella-zoster virus infection with gastrointestinal prodromal symptoms during daratumumab therapy for relapsed and refractory multiple myeloma. [PDF]

open access: yesIDCases
Horigome Y   +9 more
europepmc   +1 more source

Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments

open access: yes, 2017
Mineji Hayakawa Emergency and Critical Care Center, Hokkaido University Hospital, Sapporo, Japan Abstract: Sepsis and septic shock are frequently complicated by disseminated intravascular coagulation (DIC), which decreases the survival rate of patients ...
Hayakawa M
core  

Hydrogels Augmented With Artificial Sweeteners can Inhibit Multidrug‐Resistant Acinetobacter baumannii Growth and Biofilm Formation While Demonstrating Safety in Pre‐Clinical Pilot Human Trials

open access: yesAdvanced Healthcare Materials, EarlyView.
Using PVA–borax hydrogels as carriers for off‐the‐shelf artificial sweeteners to fight multidrug‐resistant A. baumannii. These soft, biocompatible hydrogels rapidly reduce bacterial viability within multidrug‐resistant A. baumannii biofilms by more than 99% within one hour and sustain antimicrobial activity over time, while demonstrating safety in both
Jie Han   +4 more
wiley   +1 more source

Patient‐Derived 3D Heart‐On‐a‐Chip Model of Dilated Cardiomyopathy With Embedded Bead‐Based Mapping of Tissue Contractility

open access: yesAdvanced Healthcare Materials, EarlyView.
A heart‐on‐a‐chip model of dilated cardiomyopathy is developed from patient‐derived induced pluripotent stem cells. The model recapitulates key disease phenotypes and enables functional assessment through integrated bead‐based tracking and pillar deflection measurements.
Ali Mousavi   +10 more
wiley   +1 more source

Disseminated intravascular coagulation, dic

open access: yes, 1997
Disseminated intravascular coagulation, dic. Cerebral cortex, ome 24-77.

core  

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

open access: yesAdvanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy